

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

PROFIT WARNING

This announcement is made by SoftMedx Healthcare Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of The Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company wishes to inform the shareholders and potential investors of the Company that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 and the information available to the board, the Group expects to record a significant loss of approximately HK\$405 million for the year due to a fair value loss in debt settlement in specie of approximately HK\$412 million. Such loss arose from the difference between the issue price of HK\$0.01 per share for the 1,800 million new shares issued by the Company on 11 November 2025 for loan settlement and the then closing price of HK\$0.239 per share on the same date. This fair value loss, which was one-off and non-cash in nature, impacts on the Group’s statement of profit and loss and statement of changes in equity only. There is no impact on the balance sheet, cashflow nor net asset value of the Group. Excluding such exceptional items, the Group would have recorded a net profit of approximately HK\$10 million in its ordinary course of business in comparison with the net profit of HK\$6.9 million (excluding exceptional items) for 2024.

The results of the Group are still being finalized and the information contained in this announcement is only a preliminary assessment by the board based on the unaudited consolidated management accounts of the Group and the information currently available, which have not been audited or reviewed by the Company’s auditors nor were they reviewed by the audit committee of the Company. Shareholders and potential investors are therefore advised to read carefully the annual results announcement of the Group for the year ended 31 December 2025, which is expected to be released on 27 March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 25 March 2026

As at the date of this announcement, the board of directors comprises Mr. Lin Pinzhao as executive Director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive directors.